-
Views
-
Cite
Cite
Christopher J. Westley, Richard L. Amdur, Michael S. Irwig, High Rates of Depression and Depressive Symptoms Among Men Referred for Borderline Testosterone Levels, The Journal of Sexual Medicine, Volume 12, Issue 8, August 2015, Pages 1753–1760, https://doi.org/10.1111/jsm.12937
- Share Icon Share
ABSTRACT
Men referred for borderline testosterone levels represent an increasingly common clinical scenario, yet there is little literature on this population.
We hypothesized that men referred for borderline testosterone levels would have higher rates of depression and depressive symptoms than the general population.
Subjects included 200 adult men (mean age of 48 years old) referred for borderline total testosterone levels between 200 and 350 ng/dL (6.9–12 nmol/L). Collected data included demographic information, medical histories, medication use, signs and symptoms of hypogonadism, and assessments of depressive symptoms and/or a known diagnosis of depression or use of an antidepressant.
The main outcome measure was a combination of known depression, current use of an antidepressant, and/or depressive symptoms according to the Patient Health Questionnaire 9 (PHQ‐9) with scores ≥10 considered positive.
Depression and/or depressive symptoms were present in 56% of the subjects. This rate was significantly higher than rates of 6–23% (PHQ‐9 scores ≥10) seen in general populations. Antidepressant use was 25%. The population was notable for high rates of overweight/obesity and physical inactivity. Common symptoms were erectile dysfunction, decreased libido, fewer AM erections, low energy, and sleep disturbances.
While sexual and nonspecific symptoms (i.e., fatigue) likely prompted measurements of testosterone in this selected population, clinicians should recognize the high rates of depression and depressive symptoms in men referred for borderline testosterone levels. Clinicians should consider screening for depression/depressive symptoms and overweight and unhealthy lifestyle risk factors in men referred for tertiary care for potential hypogonadism.